Status:

COMPLETED

Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment

Lead Sponsor:

FHI 360

Collaborating Sponsors:

Kenya National AIDS & STI Control Programme

Ministry of Medical Services, Kenya

Conditions:

Male Circumcision

Eligibility:

MALE

18-54 years

Phase:

NA

Brief Summary

The objective of this research study is to evaluate the safety and acceptability of the Shang Ring method of medical male circumcision. The Shang Ring is a new circumcision device with a potential rol...

Detailed Description

The objective of this research study is to evaluate the safety and acceptability of the Shang Ring method of medical male circumcision. The Shang Ring is a new circumcision device with a potential rol...

Eligibility Criteria

Inclusion

  • Must be aged 18 and 54 years;
  • Must be uncircumcised (on examination);
  • Must be in good general health;
  • Must be HIV sero-negative, with documentation of testing no mor than one week before the procedure;
  • Must be free of genital ulcerations or other visible signs of sexually transmissible infections(STI) on examination;
  • Must be able to understand study procedures and requirements of study participation;
  • Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision;
  • Must freely consent to participate in the study and sign a written informed consent form;
  • Must have a cell phone or access to a cell phone; and,
  • Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion

  • Has a known allergy or sensitivity to lidocaine or other local anesthesia;
  • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
  • Has an active genital infection, anatomic abnormality or other condition, which in the opinion of the surgeon, prevents the man from undergoing a circumcision;
  • Has known bleeding/clotting disorder (e.g. hemophilia); and,
  • Has thalassemia (an inherited autosomal recessive blood disease).

Key Trial Info

Start Date :

September 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT01247844

Start Date

September 1 2010

End Date

January 1 2011

Last Update

March 6 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Homa Bay District Hospital

Homa Bay, Nyanza, Kenya, 40300